Search Results 61-70 of 4450 for Diffuse

  1. An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) - Mayo Clinic

    The purpose of this study is treatment with HZN-825 in participants with diffuse cutaneous systemic sclerosis. Participation eligibility. Participant ...

  2. A Trial to Evaluate the Effectiveness, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis - Mayo Clinic

    The primary purpose of this study is to demonstrate the effectiveness of 1 or 2 dose levels of HZN-825 versus placebo in subjects with diffuse cutaneous ...

  3. A Study of R-ICE and Lenalidomide for Treating Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma - Mayo Clinic

    ... diffuse large B-cell lymphoma that has returned after a period of ... Giving lenalidomide with R-ICE may be a better treatment for patients with diffuse large B- ...

  4. Cutaneous B-cell lymphoma - Survival rates - Mayo Clinic

    Intravascular diffuse large B-cell lymphoma. Current data for this type shows how many people are living three years after their diagnosis. When only in the ...

  5. Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma - Mayo Clinic

    Clinical Trials · Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma · More about research at Mayo ...

  6. Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma - Mayo Clinic

    Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma · Share · Facebook · Twitter.

  7. Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma - Mayo Clinic

    Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma · Overview · Participation eligibility · Participating Mayo Clinic ...

  8. A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - Mayo Clinic

    A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · Share · Facebook ...

  9. Non-Hodgkin lymphoma - Survival rates - Mayo Clinic

    For stage 4 diffuse large B-cell lymphoma, the chance of surviving at least five years is about 55%. Follicular lymphoma is another common type of non-Hodgkin ...

  10. David J. Daniels, M.D., Ph.D. - Mayo Clinic Faculty Profiles

    Diffuse intrinsic pontine glioma; Atypical teratoid rhabdoid tumor; Pediatric glioblastoma. Significance to patient care. Dr. Daniels' lab has identified ...